Hexarelin

Journal of analytical toxicology · 2025

Researchers studied alexamorelin, a synthetic peptide that may enhance performance, to identify its consumption biomarkers for better doping control. They found that after processing in the liver, alexamorelin significantly decreased, with only one metabolite detected, which is not specific to alexamorelin use.

• Researchers identified 21 potential metabolites of alexamorelin, with N-acetylation being the most likely transformation.
• After incubating alexamorelin with liver cells, its levels dropped significantly, indicating rapid metabolism.
• Only one metabolite, examorelin, was detected, but it is commercially available and not unique to alexamorelin consumption.

European journal of medical research · 2023

Researchers found that Hexarelin, a compound tested in rats, offers protection against acute kidney injury caused by reduced blood flow. The study observed that Hexarelin reduces cell death in kidney cells and improves kidney function by influencing specific proteins involved in the cell death process.

• Hexarelin significantly mitigated kidney damage and improved function in a rat model of acute kidney injury.
• The compound reduced cell death by altering the expression of key proteins related to apoptosis.
• Molecular analysis suggested that Hexarelin interacts with MDM2, which plays a role in regulating cell survival.

Heliyon · 2020

Researchers studied existing FDA-approved drugs to see if they could effectively interact with a key protein in the SARS-CoV-2 virus that helps it replicate. They found several drugs, including Ornipressin and Lypressin, that bind strongly to this protein, suggesting they could be potential candidates for further investigation in treating COVID-19.

• Researchers observed that the crystal structure of the SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) was determined, revealing its reliance on specific viral cofactors.
• The study screened 7,922 FDA-approved drugs and identified several that interact significantly with the active site of RdRp.
• Notable candidates include Ornipressin and Lypressin, which showed strong binding within the RdRp's binding pockets.

International journal of molecular sciences · 2018

Researchers observed that the CD36-PPARγ pathway plays a significant role in regulating glucose and energy metabolism. They found that growth hormone releasing peptides (GHRP) can activate PPARγ, offering a new way to influence metabolic functions related to conditions like diabetes and atherosclerosis.

• Researchers found that activating PPARγ can improve insulin resistance in diabetic patients.
• The study identified GHRP as a potent activator of PPARγ through the scavenger receptor CD36.
• Findings suggest that the GHRP-CD36-PPARγ pathway could help manage various metabolic disorders.

Endocrine · 2015

Researchers reviewed the roles of ghrelin and its synthetic version, hexarelin, in diabetes and related heart diseases. They found that these compounds may help protect insulin-producing cells and improve glucose and fat metabolism, suggesting potential therapeutic benefits for diabetes management and heart health.

• Researchers observed that ghrelin and hexarelin can enhance the regeneration of insulin-producing beta cells.
• The study found that these compounds may improve glucose levels and insulin secretion.
• Researchers noted that ghrelin and hexarelin have beneficial effects on cardiovascular health independent of growth hormone.

Journal of geriatric cardiology : JGC · 2014

Researchers observed that hexarelin, a synthetic peptide similar to ghrelin, may have direct effects on the heart and blood vessels, suggesting potential cardiovascular benefits. The study highlights hexarelin's stability and potency compared to ghrelin, indicating it could be a promising candidate for treating certain heart conditions.

• Hexarelin activates growth hormone receptors in the brain and has direct cardiovascular effects.
• It binds to a specific cardiac receptor, CD36, which mediates its protective effects on the heart.
• Hexarelin is more stable and potent than its natural counterpart, ghrelin.

BioMed research international · 2014

Researchers reviewed various theories and mechanisms related to ageing and longevity, highlighting the complexity of these processes. They found that factors like oxidative stress, metabolism, and inflammation play significant roles, with caloric restriction and specific biological pathways showing promise for promoting a longer life.

• Researchers observed that multiple biological pathways, including those related to oxidative stress and metabolism, are involved in the ageing process.
• The review identified caloric restriction and the target of rapamycin (TOR) as potential strategies for enhancing longevity.
• Researchers noted that sirtuins and hormetic responses may also contribute to the understanding of ageing and longevity.

Methods and findings in experimental and clinical pharmacology · 2002

Researchers compiled a comprehensive guide to recent clinical trials involving various drugs, including treatments for conditions like HIV, cancer, and mental health disorders. This study highlights the ongoing research efforts and the wide range of medications currently being tested in clinical settings.

• The guide includes information on numerous drugs such as adalimumab, metformin, and trastuzumab.
• Researchers observed a focus on both established and emerging therapies across multiple health conditions.
• The data was sourced from a specialized drug discovery and development portal, ensuring up-to-date information.

European journal of endocrinology · 1997

Researchers reviewed growth hormone-releasing peptides (GHRPs), which are synthetic compounds that stimulate the release of growth hormone in both animals and humans. They found that GHRPs can effectively increase growth hormone levels through various mechanisms and have potential clinical applications for certain conditions related to growth hormone deficiency.

• GHRPs have a significant and dose-related effect on growth hormone release, which persists even with different methods of administration.
• The effectiveness of GHRPs varies with age, being highest in children and decreasing in older adults, but remains more potent than natural growth hormone-releasing hormone (GHRH).
• GHRPs maintain their ability to stimulate growth hormone release in certain conditions, such as acromegaly and hyperthyroidism, but may be less effective in others like obesity and hypothyroidism.